InvestorsHub Logo
Followers 20
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: ALL-IN888 post# 1278

Saturday, 03/30/2019 5:41:22 PM

Saturday, March 30, 2019 5:41:22 PM

Post# of 1435
Cantor Fitzgerald is low balling the PT for now, but i`m good with it......

“. We are initiating coverage of TG Overweight rating and $17 12-month price target. We believe umbralisib (PI3K inhibitor) and ublituximab (anti-CD20) have attractive profiles in oncology and autoimmune B-cell diseases. We view both lead assets as clinically de-risked with proven targets, but we think investors are cautious on the PI3K commercial potential and give no credit to multiple sclerosis (MS) due to the competitive yet price sensitive landscape. Our thesis is that next-generation assets with a differentiated profile can gain share in late-stage lymphoma and that competing on price in MS with a similar drug can drive share.”,” Cantor Fitzgerald’s analyst wrote.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TGTX News